IQVIA Holdings, Inc.
IQV
$261.77
+1.74%
IQVIA Holdings Inc. is a global leader in clinical research and technology solutions for the life sciences industry, operating through two primary segments: Research & Development Solutions, which provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, and regulatory approval, and Commercial Solutions, which helps biopharmaceutical companies optimize product commercialization through analytics, technology, and outsourced sales services. Formed in 2016 from the merger of Quintiles and IMS Health, the company occupies a distinctive position at the intersection of clinical trial execution and healthcare data analytics, making it both a services provider and a data platform company with few direct peers at scale. The current investor narrative centers on IQVIA's accelerating revenue growth — Q1 2026 revenue rose 8.4% year-over-year to $4.15 billion — and the market's growing appreciation for its AI-enabled data assets as a competitive moat in drug development. However, the stock's dramatic re-rating over the past six months, including a sharp single-day jump in late July 2026, has shifted the debate from "is it undervalued?" to "how much growth is already priced in?" Analyst sentiment remains strongly constructive, with a consensus rating of strong buy and an average target of $276.28, though the wide $240–$300 target range reflects lingering uncertainty about the durability of the current growth trajectory.…
IQV
IQVIA Holdings, Inc.
$261.77
Related headlines
Investment Opinion: Should I buy IQV Today?
IQVIA warrants a Hold rating, balancing its strong fundamentals and growth prospects against a valuation that already reflects much of the optimism. The analyst consensus is a strong buy with an average target of $276.28, implying only 5.5% upside from the current price of $261.77. While the company's revenue growth is re-accelerating (8.41% YoY in Q1 2026) and free cash flow is robust ($2.545B TTM), the stock's 58.92% six-month rally has pushed it to 91.5% of its 52-week range, leaving limited margin of safety.
The supporting evidence for a Hold includes: 1) Forward PE of 18.10x, which is attractive if earnings grow as expected, but the trailing PE of 28.50x and PEG of 6.34 suggest the stock is not cheap; 2) Revenue growth has accelerated from 5.23% in Q3 2025 to 8.41% in Q1 2026, but margins have contracted (gross margin down to 32.64% from 33.90% a year ago); 3) Free cash flow yield of 6.6% provides some downside protection, but the debt-to-equity ratio of 2.49 and current ratio of 0.75 indicate financial leverage; 4) The implied upside to the average analyst target is only 5.5%, and the low target of $240 suggests 8.3% downside. Compared to the broader market, IQV's relative strength has been exceptional, but this also means it is vulnerable to profit-taking.
The biggest risks that could invalidate the Hold rating include a slowdown in revenue growth below 5%, further margin compression, or a rise in interest rates increasing the cost of debt. The rating would upgrade to Buy if the stock pulls back to the $230-$240 range (near the low analyst target) or if forward PE compresses below 16x while growth remains above 8%. It would downgrade to Sell if revenue growth decelerates below 5% or if operating margins fall below 12%. Overall, IQV appears fairly valued relative to its history and peers, with the forward PE offering a more reasonable entry point than trailing metrics, but the stock is not undervalued after its recent surge.
Sign up to view all
IQV 12-Month Price Forecast
IQVIA presents a balanced risk/reward profile at current levels. The company's re-accelerating revenue growth and robust free cash flow are positives, but the stock's 58.92% six-month rally has already priced in much of the near-term optimism, leaving only 5.5% upside to the average analyst target. The forward PE of 18.10x is attractive relative to the trailing PE of 28.50x, but this relies on aggressive earnings growth that may be challenging given margin pressures and high leverage. The neutral stance reflects the tug-of-war between strong fundamentals and a full valuation. I would upgrade to bullish if the stock pulls back to the $230-$240 range or if revenue growth accelerates above 10% with margin expansion. I would downgrade to bearish if revenue growth decelerates below 5% or if operating margins fall below 12%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on IQVIA Holdings, Inc.'s 12-month outlook, with a consensus price target around $276.28 and implied upside of +5.5% versus the current price.
Average Target
$276.28
0 analysts
Implied Upside
+5.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$240 - $300
Analyst target range
IQVIA is covered by 18 analysts, and the consensus recommendation is a strong buy with a recommendation mean of 1.43 (where 1.0 is a strong buy and 5.0 is a strong sell). The average price target is $276.28, which implies approximately 5.5% upside from the current price of $261.77. This relatively modest upside to consensus, despite the strong buy rating, suggests that analysts have been scrambling to raise targets to keep pace with the stock's rapid ascent — the stock has gained 44.26% over the past three months alone, and the average target may lag the current price momentum. The consensus is clearly bullish, but the narrow implied upside indicates that much of the near-term optimism is already reflected in the stock price.
The target price range spans from a low of $240.00 to a high of $300.00, a spread of $60.00 or approximately 25% of the low target. The high target of $300 implies roughly 14.6% upside and likely assumes continued revenue acceleration, margin expansion, and multiple expansion driven by AI-related data monetization and strong clinical trial demand. The low target of $240 implies approximately 8.3% downside and likely prices in slower growth, competitive pressures in the CRO space, or margin compression from wage inflation and higher interest costs. The institutional ratings data shows a predominantly constructive tone: recent actions include Mizuho maintaining Outperform (July 2026), Baird maintaining Outperform (July 2026), TD Cowen upgrading to Buy from Hold (March 2026), and Barclays upgrading to Overweight from Equal Weight (March 2026). The notable exception is Morgan Stanley downgrading to Equal Weight from Overweight in June 2026, which may reflect valuation concerns after the stock's sharp run-up. The wide target spread and the mix of upgrades and a downgrade suggest that while the fundamental story is strong, there is genuine debate about how much of the growth is already priced in at current levels.
Bulls vs Bears: IQV Investment Factors
The bull case for IQVIA rests on re-accelerating revenue growth (8.41% YoY in Q1 2026), strong free cash flow ($2.545B TTM), and a forward PE of 18.10x that appears reasonable if earnings growth materializes. The bear case centers on elevated leverage (D/E 2.49), premium trailing valuation (PE 28.50x, PEG 6.34), and technical overextension after a 58.92% six-month rally that leaves only 5.5% upside to the average analyst target. Currently, the bull evidence is stronger due to the company's consistent cash generation, analyst consensus (strong buy), and the forward earnings growth implied by the 36.5% PE compression. The single most important tension is whether IQVIA can sustain its revenue acceleration and margin expansion to justify the forward earnings expectations; if growth decelerates or margins compress further, the stock could face a significant de-rating given its premium trailing multiples.
Bullish
- Revenue growth re-accelerating: Q1 2026 revenue grew 8.41% YoY to $4.151B, up from 5.23% in Q3 2025 and 10.25% in Q4 2025, signaling a recovery from the mid-single-digit deceleration in mid-2025. The R&D Solutions segment, at 57.7% of revenue, remains the primary growth engine.
- Strong buy consensus with upside: 18 analysts rate IQV a strong buy (mean 1.43), with an average target of $276.28 implying 5.5% upside and a high target of $300 implying 14.6% upside. Recent upgrades from TD Cowen and Barclays in March 2026 reinforce positive sentiment.
- Robust free cash flow generation: TTM free cash flow is $2.545B, yielding approximately 6.6% FCF yield on the $38.75B market cap. Q1 2026 FCF was $491M on operating cash flow of $618M, funding $552M in share repurchases and $163M in debt repayment.
- Attractive forward valuation: Forward PE of 18.10x is well below the trailing PE of 28.50x, implying 36.5% earnings growth is expected. Consensus EPS estimate of $20.78 for the forward period supports this, making the stock reasonably valued on forward earnings.
Bearish
- Elevated leverage and liquidity concerns: Debt-to-equity is 2.49 and the current ratio is 0.75, indicating current liabilities exceed current assets. Quarterly interest expense of $192M is a significant fixed cost, consuming a large portion of operating income.
- Premium valuation on trailing metrics: Trailing PE of 28.50x and PEG of 6.34 suggest the stock is expensive relative to its growth rate. EV/EBITDA of 15.28x is on the higher end for a CRO, and the forward PE of 18.10x relies on aggressive earnings growth that may not materialize.
- Overextended technicals: The stock has nearly doubled from its 52-week low of $154.50 and is trading at 91.5% of its 52-week range. The max drawdown of -35.87% shows vulnerability to sharp corrections, and the recent 44% three-month gain raises mean-reversion risk.
- Margin pressure and earnings volatility: Gross margin declined to 32.64% in Q1 2026 from 33.90% in Q1 2025, and operating margin fell to 12.38% from 12.95%. Net margin of 6.60% is thin, and the trailing EPS of $0.035 is distorted, highlighting earnings quality concerns.
IQV Technical Analysis
IQVIA is in a powerful, sustained uptrend that has carried the stock 37.28% higher over the past year and 58.92% over the past six months, dramatically outperforming the S&P 500's 16.22% and 15.40% gains over the same periods. At a current price of $261.77, the stock is trading at approximately 91.5% of its 52-week range (52-week low of $154.50, high of $271.80), placing it firmly in the upper echelon of its annual trading band. This positioning signals strong momentum but also raises the risk of overextension, particularly given that the stock has nearly doubled from its 52-week low and is within roughly 4% of its 52-week high. The 52-week range itself is remarkably wide at $117.30, reflecting the stock's journey from a deep drawdown — the max drawdown of -35.87% suggests a significant prior correction — to its current recovery and breakout phase.
Short-term momentum is decisively positive and accelerating: the stock has gained 8.30% over the past month and 44.26% over the past three months, with the 3-month gain far outpacing the 1-year gain of 37.28%, indicating that the bulk of the annual return has been generated in just the last quarter. This acceleration is corroborated by relative strength metrics — IQV has outperformed SPY by 9.36 percentage points over the past month, 41.22 points over three months, and 43.52 points over six months, while the S&P 500 actually declined 1.06% over the past month. The divergence between IQV's strong positive 1-month return (+8.30%) and SPY's negative 1-month return (-1.06%) suggests IQV is exhibiting defensive growth characteristics and attracting rotation capital. However, the YTD gain of 16.15% is notably smaller than the 6-month gain of 58.92%, implying that the stock experienced a weak first quarter of 2026 before staging a dramatic recovery — a pattern that warrants monitoring for potential mean reversion.
Key technical levels are well-defined: the 52-week high of $271.80 serves as the primary resistance level, and a decisive breakout above this threshold — particularly on elevated volume — would signal a continuation of the uptrend and likely invite momentum-driven buying. Conversely, the 52-week low of $154.50 represents major support, though intermediate support likely exists around the $230–$240 zone where the stock consolidated in early August 2026. With a beta of 1.186, IQV is approximately 18.6% more volatile than the broader market, meaning position sizing should account for amplified drawdown risk during market corrections. The short ratio of 3.0 indicates moderate short interest, which could fuel a short squeeze on a breakout above resistance but is not extreme enough to be a primary driver of price action.
Beta
1.19
1.19x market volatility
Max Drawdown
-35.9%
Largest decline past year
52-Week Range
$155-$272
Price range past year
Annual Return
+37.3%
Cumulative gain past year
| Period | IQV Return | S&P 500 |
|---|---|---|
| 1m | +8.3% | -1.6% |
| 3m | +44.3% | +1.3% |
| 6m | +58.9% | +13.9% |
| 1y | +37.3% | +16.3% |
| ytd | +16.2% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IQV Fundamental Analysis
IQVIA's revenue trajectory is clearly positive and accelerating: Q1 2026 revenue reached $4.151 billion, representing 8.41% year-over-year growth from $3.829 billion in Q1 2025. This marks an acceleration from the prior quarters — Q4 2025 revenue of $4.364 billion grew 10.25% YoY from $3.958 billion in Q4 2024, while Q3 2025 revenue of $4.10 billion grew 5.23% from $3.896 billion in Q3 2024. The Research & Development Solutions segment contributed $2.397 billion in the most recent quarter, representing approximately 57.7% of total revenue and serving as the primary growth engine. The multi-quarter trend shows revenue oscillating between $4.0 billion and $4.4 billion with a generally upward slope, and the YoY growth rate recovering from the mid-single digits in mid-2025 to the 8–10% range by late 2025 and early 2026, suggesting the company has moved past a period of growth deceleration and is re-accelerating.
Profitability is solid and improving on a sequential basis. Q1 2026 net income was $274 million on $4.151 billion in revenue, yielding a net margin of 6.60%, up from 6.50% in Q1 2025 and 6.62% in Q2 2025. Gross margin in Q1 2026 was 32.64%, relatively stable compared to 33.90% in Q1 2025 and 32.94% in Q2 2025, though the Q4 2025 figure of 6.69% appears anomalous due to a reported cost of revenue of $4.072 billion that likely reflects a one-time accounting adjustment or reclassification. Operating income in Q1 2026 was $514 million, translating to a 12.38% operating margin, up from 12.95% in Q1 2025 and 12.60% in Q2 2025. The company's trailing twelve-month net margin of 8.34% and operating margin of 14.02% (per valuation data) are consistent with a mature, asset-light services and analytics business, though they trail the higher margins typical of pure-play software companies, reflecting the labor-intensive nature of clinical trial execution.
IQVIA's balance sheet carries meaningful leverage but is supported by robust cash generation. The debt-to-equity ratio stands at 2.49, and the current ratio of 0.75 indicates that current liabilities exceed current assets — a common characteristic of companies with large deferred revenue and receivables balances rather than a sign of liquidity distress. Free cash flow on a trailing twelve-month basis is $2.545 billion, and Q1 2026 free cash flow was $491 million on operating cash flow of $618 million, with capital expenditures of $127 million. The company returned capital aggressively, repurchasing $552 million in stock during Q1 2026 alone, funded partly by $163 million in debt repayment and $433 million in net financing outflows. Return on equity is a healthy 20.91%, and return on assets is 5.06%, indicating efficient use of capital despite the leveraged structure. The FCF yield of approximately 6.6% (based on $2.545 billion FCF against a $38.75 billion market cap) provides a reasonable cushion, though the high debt load means interest expense of $192 million per quarter remains a meaningful fixed cost.
Quarterly Revenue
$4.2B
2026-03
Revenue YoY Growth
+8.4%
YoY Comparison
Gross Margin
32.6%
Latest Quarter
Free Cash Flow
$2.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IQV Overvalued?
Because IQVIA is profitable — Q1 2026 net income of $274 million and trailing EPS of $0.035 (which appears distorted by non-recurring items) — the PE ratio is the appropriate primary valuation metric. The trailing PE of 28.50x compares to a forward PE of 18.10x, a dramatic 36.5% compression that implies the market expects substantial earnings growth over the next twelve months. This gap is corroborated by the consensus EPS estimate of $20.78 for the forward period, which would represent a massive increase from the trailing figure — though the trailing EPS of $0.035 appears to be an outlier, likely reflecting a significant one-time charge or accounting distortion, making the forward PE the more reliable valuation anchor. The PEG ratio of 6.34 is elevated, suggesting that even after accounting for growth, the stock trades at a premium to its earnings expansion rate.
Relative to the broader healthcare and diagnostics sector, IQVIA's valuation presents a mixed picture. The price-to-sales ratio of 2.38x and EV/Sales of 3.34x are moderate for a company with a 26.28% gross margin and 14.02% operating margin, though the EV/EBITDA of 15.28x is on the higher end for a clinical research organization. The price-to-book ratio of 5.96x reflects the company's asset-light model and significant goodwill from the Quintiles-IMS Health merger. Without explicit industry average multiples in the provided data, a qualitative assessment suggests IQVIA trades at a premium to traditional CRO peers (which typically command 12–16x forward earnings) but at a discount to healthcare data and analytics platforms, reflecting its hybrid business model. The forward PE of 18.10x is arguably reasonable for a company growing revenue at 8–10% with expanding margins, though the trailing PE of 28.50x suggests the market has already priced in a significant earnings recovery.
Historically, IQVIA's PE ratio has ranged from a low of approximately 18.66x (Q4 2025) to a high of 44.03x (Q3 2021), with the current trailing PE of 28.50x sitting near the middle of that range. The PS ratio tells a more cautionary story: the current 2.38x is near the low end of the historical range, which has spanned from roughly 6.74x (Q2 2025) to 14.81x (Q4 2021) — though this comparison is complicated by the fact that the current PS ratio is calculated on a different share count and revenue base than the historical quarterly figures. The PB ratio of 5.96x is near the lower end of its historical band of approximately 4.62x to 8.91x, suggesting the stock is not expensive on a book value basis relative to its own history. Overall, the valuation appears full but not extreme, with the forward PE of 18.10x providing a more constructive entry point than the trailing metrics suggest.
PE
28.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~44x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.3x
Enterprise Value Multiple
Investment Risk Disclosure
IQVIA's financial risks are primarily tied to its leveraged balance sheet and thin margins. The debt-to-equity ratio of 2.49 and current ratio of 0.75 indicate a heavy debt burden and potential liquidity tightness, though the current ratio is typical for companies with large deferred revenue. Interest expense of $192 million per quarter consumes a substantial portion of operating income ($514 million in Q1 2026), leaving limited cushion if rates rise or earnings decline. Additionally, net margin is only 6.60%, and gross margin has declined from 33.90% in Q1 2025 to 32.64% in Q1 2026, suggesting pricing pressure or cost inflation. The company's reliance on the R&D Solutions segment (57.7% of revenue) also concentrates risk; any slowdown in clinical trial activity or loss of a major client could disproportionately impact results.
Market and competitive risks include valuation compression and sector rotation. IQV trades at a trailing PE of 28.50x and a PEG of 6.34, which is rich relative to its growth rate and leaves little room for error. The stock's beta of 1.186 means it is 18.6% more volatile than the market, amplifying downside during corrections. Competition from other CROs and healthcare data providers could pressure pricing and market share, while regulatory changes in drug development or healthcare data privacy could increase compliance costs. Recent news highlights AI momentum in healthcare (e.g., VEEV's raised outlook), which could attract capital away from traditional CROs if IQVIA fails to demonstrate comparable AI-driven differentiation. The Morgan Stanley downgrade in June 2026 underscores growing concerns about the stock's valuation after its sharp run-up.
The worst-case scenario would involve a combination of slowing revenue growth, margin compression, and multiple contraction. If revenue growth decelerates below 5% and operating margins fall below 12%, the forward PE of 18.10x could expand as earnings estimates are revised downward, leading to a de-rating. In this scenario, the stock could retest its 52-week low of $154.50, representing a 41% decline from the current price of $261.77. The analyst low target of $240 implies a more moderate 8.3% downside, but historical max drawdown of -35.87% suggests that steeper declines are possible during adverse market conditions. Investors could lose 35-40% from current levels if the growth narrative unravels.
FAQ
The key risks for IQV include: 1) Financial risk: high leverage with debt-to-equity of 2.49 and current ratio of 0.75, plus quarterly interest expense of $192M that consumes a large portion of operating income. 2) Valuation risk: trailing PE of 28.50x and PEG of 6.34 leave little room for error; any growth disappointment could trigger a sharp de-rating. 3) Competitive risk: the CRO and healthcare data markets are highly competitive, and rivals like VEEV are gaining AI momentum, which could pressure IQVIA's market share. 4) Macro risk: a slowdown in biopharma R&D spending or rising interest rates could reduce demand and increase financing costs. The most severe risk is a combination of slowing revenue growth and margin compression, which could push the stock down to the 52-week low of $154.50, representing a 41% decline from current levels.
Our 12-month forecast for IQV includes three scenarios: Bull case (25% probability) with a target range of $300-$320, assuming revenue growth exceeds 10% and margins expand; Base case (55% probability) with a target range of $260-$285, assuming 8-10% revenue growth and stable margins; Bear case (20% probability) with a target range of $200-$240, assuming growth decelerates below 5% and margins compress. The base case is most likely, aligning with the analyst average target of $276.28. The key assumption is that IQVIA maintains its revenue growth trajectory and avoids major margin erosion. However, the risk/reward is skewed to the downside given the limited upside to the average target and the stock's recent sharp rally.
IQV appears fairly valued to slightly overvalued on trailing metrics but reasonably valued on forward earnings. The trailing PE of 28.50x is near the middle of its historical range (18.66x to 44.03x), while the forward PE of 18.10x is attractive if earnings grow as expected. The PEG ratio of 6.34 suggests the stock is expensive relative to its growth rate, and the EV/EBITDA of 15.28x is on the higher end for a CRO. Compared to peers, IQV trades at a premium to traditional CROs but at a discount to pure-play healthcare data platforms, reflecting its hybrid model. The market is pricing in significant earnings growth (consensus EPS of $20.78) and margin expansion, which may be challenging given the 2.49 debt-to-equity ratio and thin net margin of 6.60%. Overall, the stock is not undervalued; it is priced for continued execution.
IQV is a good buy for growth-oriented investors with a long-term horizon, but the current entry point offers limited upside. The stock trades at $261.77, with an average analyst target of $276.28 implying only 5.5% upside, and a low target of $240 suggesting 8.3% downside. The company's revenue growth is re-accelerating (8.41% YoY in Q1 2026) and free cash flow is strong ($2.545B TTM), but the trailing PE of 28.50x and PEG of 6.34 indicate a premium valuation. The biggest downside risk is a growth slowdown or margin compression, which could lead to a de-rating. For investors with a high risk tolerance and a 2-3 year horizon, IQV offers exposure to the secular growth of clinical research outsourcing and healthcare data analytics. However, those seeking value or income should look elsewhere, as the stock pays no dividend and appears fully valued after its 58.92% six-month rally.
IQV is more suitable for long-term investment (2-3 years or more) than short-term trading. The company operates in a secular growth industry with high barriers to entry, and its revenue is re-accelerating, which should drive earnings growth over time. However, the stock's beta of 1.186 and recent 58.92% six-month rally make it volatile in the short term, and the lack of a dividend (payout ratio 0) means no income component. Short-term traders might find opportunities around earnings or technical breakouts, but the limited upside to analyst targets suggests the easy money has been made. For long-term investors, IQV offers exposure to the growing outsourcing of clinical trials and healthcare data analytics, but a pullback to the $230-$240 range would provide a more attractive entry point. A minimum holding period of 2-3 years is recommended to ride out volatility and benefit from earnings growth.